Citations

Clear

136 citation(s) found for "Sherif, A".

Artificial intelligence based multimodal fusion of electronic medical record data and ECG signals for pericarditis prediction: pericarditis calculator (p-Cal) as a screening aid
Ayoub, Chadi, Pi, Jialu, Pereyra, Milagros , Ahmed, Sherif , Crystal, Owen, Oh, Jae K, Arsanjani, Reza, Banerjee, Imon, Ahmed, Sherif , Luis, Sushil A , Pereyra, Milagros , Farina, Juan M. , Crystal, Owen , Luis, Sushil Allen , Arsanjani, Reza , Banerjee, Imon

Mayo Clinic

Heart | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: heartjnl-2025-327090

10.1136/heartjnl-2025-327090 | PMID 42638076 Get It

Background Pericarditis may be associated with significant morbidity and mortality and can be a clinically challenging entity to diagnose. There is a clinical need for automated artificial intelligence (AI) algorithms to act as a screening aid to assist with the early and accurate detection of pericarditis. Methods We developed p-Cal, a browser-based pericarditis risk calculator that fuses the patient clinical data and 12-lead ECG image to estimate risk for pericarditis. The ECG encoder was designed based on a pretrained MedCLIP Vision Transformer and random forest classifier was used for the clinical tabular data. These two modalities were fused at the decision-level using a meta classifier. Model reasoning for both modalities was assessed using advanced explainable AI techniques—attention maps from the transformer model were used to interpret ECG images, while SHapley Additive exPlanations (SHAP) force plots were applied to analyse the tabular data. Results A total of 6508 patients (mean age 54.8±16.1 years, 50.9% female) were used for training and internal validation of the AI model, of whom 902 patients had a confirmed diagnosis of pericarditis (13.8%) and the remainder were normal controls. On 1302 hold-out test patients, the Fusion Model demonstrated the best discriminatory performance, achieving an area under the curve (AUC) of 0.89, which surpassed the ECG (AUC = 0.85) and the clinical data only models (AUC = 0.74) performance. On external validation in the Medical Information Mart for Intensive Care (MIMIC) Database, the fusion model achieved an AUC of 0.81. Conclusion A late fusion AI model integrating tabular clinical electronic medical record data and ECG signal has robust predictive capability for pericarditis as a screening tool.
When Time Matters in Aortic Stenosis: Can Transcatheter Aortic Valve Replacement Make a Difference in Non-Elective Cases?
Chollet, Laurève , Ahmed, Mina , Bilauca, Christine, Scalia, Isabel G., Razaghi, Mahshad , Abdelfattah, Fatmaelzahraa E., Awad, Kamal, Hafez, Abdelrahman, Ahmed, Sherif , Ayoub, Chadi, Sweeney, John P., Lester, Steven J., Lee, Kwan S., Fortuin, David, Arsanjani, Reza, Villa Etchegoyen, Cecilia , Chollet, Laurève , Etchegoyen, Cecilia Villa , Farina, Juan M. , Pereyra, Milagros , Scalia, Isabel G. , Abdelfattah, Fatmaelzahraa , Awad, Kamal , Hafez, Abdelrahman , Alsidawi, Said , Lester, Steven J., Lee, Kwan S., Fortuin, David, Sell‐Dottin, Kristen , Arsanjani, Reza

Mayo Clinic

Reviews in Cardiovascular Medicine | July 30, 2026 | Volume: 27 | Issue: 7 | Pages: No page available

10.31083/rcm49738 | PMID 42534201 Get It

Background:The development of symptoms or left ventricular dysfunction in severe aortic stenosis (AS) is associated with high morbidity and mortality. While elective transcatheter aortic valve replacement (TAVR) is supported by robust randomized evidence, data on TAVR performed in non-elective settings (urgent, emergent, or salvage) remain limited and heterogeneous. In these settings, outcomes may be influenced more by baseline clinical severity than by procedural factors. This study aimed to systematically evaluate the safety and effectiveness of non-elective TAVR and to compare the associated outcomes with those of elective TAVR.Methods:This systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and registered with PROSPERO. The PubMed, Embase, and Scopus databases were searched for studies published after 2002 evaluating urgent, emergent, or salvage TAVR in adult patients with severe AS. Eligible studies were required to include elective TAVR as a comparator. Outcomes included mortality and major procedural complications. Prespecified era-based analyses and sensitivity analyses excluding studies at critical risk of bias were performed. Risk of bias was assessed using the ROBINS-I tool.Results:A total of 17 observational studies published between 2015 and 2025 were included, comprising 215,141 patients. Compared with elective patients, those undergoing non-elective TAVR had more advanced heart failure, higher NYHA class, greater comorbidity burden, and higher surgical risk scores, whereas baseline echocardiographic severity of AS was similar. Pooled outcomes for non-elective TAVR showed in-hospital, 30-day, and 1-year mortality rates of 5.1%, 12.4%, and 26.7%, respectively. Non-elective TAVR was associated with higher mortality at all time points compared with elective procedures; meanwhile, rates of stroke, vascular complications, and permanent pacemaker implantation were similar, while major bleeding and acute kidney injury were more frequent. Era-based analyses showed a stable relative mortality risk over time.Conclusions:Although non-elective TAVR is associated with worse outcomes than elective procedures, these differences appear to be largely driven by baseline clinical severity rather than by the transcatheter intervention. In unstable patients with severe AS, non-elective TAVR remains the most effective definitive treatment option compared with balloon aortic valvuloplasty or conservative management.The PROSPERO Registration:CRD420251239620, https://www.crd.york.ac.uk/PROSPERO/view/CRD420251239620.
Long‐Term Outcomes After Retropubic and Transobturator Sling Procedures: Reoperation for Recurrent Stress Urinary Incontinence
Trad, Ayssa Teles Abrão , Nashar, Sherif A. El, Madsen, Annetta M., Occhino, John A. , Gebhart, John B. , McGree, Michaela E. , Fought, Angela J. , Trabuco, Emanuel C. , El Nashar, Sherif A, Linder, Brian J , El‐Nashar, Sherif A. , Linder, Brian J. , Madsen, Annetta M.

Mayo Clinic

BJOG: An International Journal of Obstetrics & Gynaecology | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/1471-0528.70295 | PMID 42392760 Get It

ABSTRACT Objective To evaluate long‐term failure rates and complications after retropubic and transobturator midurethral sling procedures for primary stress urinary incontinence (SUI). Design Retrospective cohort study. Setting Academic medical centre. Population A previously described cohort of patients ( n = 1881) who underwent midurethral sling procedures (2002–2012) and a covariate‐matched cohort of patients with retropubic ( n = 570) or transobturator ( n = 317) slings. Methods Health record review with follow‐up extended by 9 years (through December 31, 2022). Main Outcome Measures Treatment failure (reoperation for recurrent SUI) and procedure‐associated complications. Results The duration of assessment was extended by 6.9 years for the retropubic group and by 6.4 years for the transobturator group. The median (IQR) follow‐up was 11.1 (5.1–14.5) years (retropubic, 11.4 [5.9–14.6]; transobturator, 9.6 [2.6–13.7]). Higher risk of reoperation was observed with transobturator (8.8%) than retropubic (4.4%) slings (unadjusted hazard ratio [HR], 2.29 [95% CI, 1.49–3.54]; p < 0.001; covariate‐matched analysis HR, 1.91 [95% CI, 1.15–3.17]; p = 0.01). The increased risk of reoperation with a transobturator sling was higher when the procedure was combined with prolapse repair (unadjusted HR, 6.34 [95% CI, 3.09–13.02]; p < 0.001; covariate‐matched analysis HR, 3.96 [95% CI, 1.35–11.58]; p = 0.01). Higher rates of reoperation for urinary retention were observed for the retropubic group than for the transobturator group (covariate‐matched analysis HR, 8.39 [95% CI, 1.11–63.22]; p = 0.04). Conclusion In this long‐term follow‐up study, midurethral slings had a low failure rate. Women with SUI undergoing transobturator sling placement plus prolapse repair had a greater risk of reoperation. However, women with retropubic slings had a greater risk of urinary retention requiring intervention.
Early experience optimizing immunosuppressive use and monitoring in MyPEAK-1, a first-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy
Desai, M Y, Nagueh, S F, Giudicessi, J O H N R, Kellner, D, Pollman, M, Varfaj, B, Paterson, N A T, Harrison, W, Pushkin, R, Tomlinson, L T, Mangal, B, Argast, G, Lombardi, L, Ivey, K, Tingley, W, Desai, M Y, Nagueh, Sherif F. , Giudicessi, John R. , Kellner, Danielle, Pollman, Matthew J., Paterson, N A T, Tomlinson, LaTanya, Argast, Gretchen, Tingley, Whit

Mayo Clinic

European Journal of Heart Failure | June 29, 2026 | Volume: 28 | Issue: Supplement_2 | Pages: No page available

10.1093/ejhf/xuag193.1205 Get It

Abstract Background Immunosuppression (IS) is required in AAV-mediated gene therapy to maximize safety and efficacy, in part to mitigate potential hepatotoxicity and prevent immune-mediated loss of transgene expression. However, prolonged IS increases the risk of complications, including infections. MYBPC3-associated HCM patients have limited treatment options. MyPEAK-1 is a first-in-human trial to assess the safety and efficacy of TN-201, a gene replacement therapy, which was designed to address the underlying genetic cause of MYBPC3-associated HCM in symptomatic adults. Objective To describe the safety and refinement of the IS regimen and monitoring used during the dosing of Cohorts 1 and 2 in the MyPEAK-1 trial. Methods The dose-escalation study utilized two cohorts (n=3 each) receiving 3E13 vg/kg (Cohort 1) or 6E13 vg/kg (Cohort 2) of TN-201 as a single IV infusion. All patients received prophylactic prednisone (starting at 1 mg/kg, maximum 80 or 60 mg/day) and sirolimus (target trough level of 4–8 ng/mL). Prednisone was tapered over several weeks, with variable timing depending on safety laboratory results. The dose of prednisone and timing of sirolimus were adjusted to reduce IS burden in Cohort 2. Specifically, sirolimus was initiated earlier (Day -7 vs Day -3) and the maximum starting dose of prednisone was reduced (from 80 to 60 mg/day). Monitoring frequency was increased to weekly throughout the course of IS. An independent data safety monitoring board provided safety oversight. Results All six patients successfully completed the IS regimen. TN-201 was generally well-tolerated at both dose levels (follow-up &gt;52 weeks and &gt;12 weeks in Cohort 1 and 2, respectively). Adjustments to the IS regimen and monitoring during Cohort 1 facilitated a significantly shorter course of IS in Cohort 2, with a mean duration of prednisone use of 256 vs 81 days. Despite receiving a higher dose of TN-201, peak transaminase levels, reflecting liver inflammation, were lower in Cohort 2 than Cohort 1. There was no clinical TMA in either cohort. Mean sirolimus trough levels remained consistent between groups (7.2 vs 7.4 ng/mL). Increases in MyBP-C protein, decreases in circulating cardiac biomarkers, and a reduction in LV hypertrophy were observed during follow up. Conclusion Standardized adjustments to the prophylactic immunosuppressive regimen in the MyPEAK-1 trial successfully managed the immunogenicity of AAV9-based gene therapy. Cohort 2 patients required lower cumulative corticosteroid doses without compromising safety or cardiac transduction. These refinements enabled lower cumulative steroid exposure and shorter IS durations in the higher-dose cohort. These results suggest that individualized, protocol-driven IS is effective in controlling the immune response to TN-201 while supporting transgene expression, paving the way for continued investigation of this gene therapy clinical investigation in MYBPC3-associated HCM population.Corticosteroid duration and daily doseFor image description, please refer to the figure legend and surrounding text.
P362 Endoscopic submucosal dissection with rubber bands and clips compared to conventional endoscopic submucosal dissection: a systematic review and meta-analysis
Hassan, M, Marey, Mohamed Mahmoud, Bahnasy, Ahmed, Mohamed, Rashad G, Keshk, Menna A. , Alnomani, Yousef Radwan , Balouz, Manar A., Hussein, Ahmed Abdelgayed M, Mohamed, Fatma Saffeyeldin, Alaeb, Mohammed A., Sharaf, Mohamed S., Ahmed, Omar T. , Neknam, Nigar, Andrawes, Sherif, Awad, Abdelaziz A. , Abosheaishaa, Hazem Maarouf , Marey, Mohamed Mahmoud , Mohamed, Rashad G. , Mohamed, Fatma S, Andrawes, Sherif

Mayo Clinic

E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A298.1-A298

10.1136/gutjnl-2026-bsg.471 Get It

Deep learning based time series analysis for breathing phase prediction in phase-gated proton therapy
Qian, J. , Tang, Xueyan , Matysiak, Witold, Zhou, Mi , Stottler, Zachary Shaun, El‐Sherif, Omar , Deisher, Amanda, Tryggestad, E., Matysiak, W , Qian, Jing , Matysiak, Witold P , Stottler, Zachary S, Deisher, Amanda J, Tryggestad, Erik, Zhou, Mi , El-Sherif, Omar

Mayo Clinic

Physics in Medicine & Biology | June 17, 2026 | Volume: 71 | Issue: 13 | Pages: 135005

10.1088/1361-6560/ae7eec | PMID 42309140 Get It

Abstract Objective . Phase gating is a critical technique to mitigate tumor motion during radiotherapy, particularly in spot-scanned particle therapy where internal motion can interfere with dynamic spot scanning patterns and, simultaneously, introducing substantial range uncertainties. However, the current commercial state of the art in real-time phase prediction is challenged by patient-specific breathing variability as well as detection and delivery system latencies. This leads to suboptimal efficiency, mis-timed radiation delivery and requires frequent manual intervention. This study aims to improve phase prediction accuracy using deep learning (DL)-based time series forecasting to enable more accurate dose delivery. Approach . Retrospective breathing waveforms from 69 proton therapy patients, sampled at 30 Hz, were labeled with inspiratory peaks and assigned subjective regularity scores (four levels). DL models with various architectures were trained using waveform amplitude to predict current or future breathing phases. Model performance was evaluated using mean squared error, phase binning accuracy, and timing deviation for radiation on/off events. Bayesian optimization was used for hyperparameter tuning. Results were compared between models and against a commercial algorithm currently in clinical use. Main Results . The curated waveform dataset included 165 242 s for training, 24 057 s for validation, and 30 322 s for testing, with an additional 40 604 s from separate patients for extended validation. The long short-term memory and temporal fusion transformer models significantly outperformed the commercial algorithm, improving phase prediction accuracy by nearly 20% and reducing timing deviations across all regularity levels. Significance . DL-based time series forecasting may substantially improve breathing phase prediction accuracy over current clinically available methods, offering a more precise and reliable approach to phase-gated radiation delivery.
Artificial Intelligence-Driven Fractional Flow Reserve Assessment: Technical Foundations, Clinical Insights, and Future Directions
Hafez, Abdelrahman, Awad, Kamal, Farina, Juan M. , Nour, Mohamed , Reyad, Mohamed , Scalia, Isabel G. , Ahmed, Sherif, Abdelfattah, Fatmaelzahraa , Razaghi, Mahshad , Chollet, Laurève , Ibrahim, Ramzi, Tamarappoo, Balaji, Stib, Matthew, Ayoub, Chadi , Arsanjani, Reza , Mohamed, Mohamed Reyad , Villa Etchegoyen, Cecilia , Arsanjani, Reza , Farina, Juan M , Scalia, Isabel G , Hafez, Abdelrahman , Awad, Kamal , Ahmed, Sherif , Etchegoyen, Cecilia Villa , Ibrahim, Ramzi , Stib, Matthew T.

Mayo Clinic

Medicina | June 15, 2026 | Volume: 62 | Issue: 6 | Pages: 1157

10.3390/medicina62061157 | PMID 42356169 Get It

Coronary artery disease (CAD) remains a leading cause of global morbidity and mortality. Accurate diagnosis of ischemia-causing coronary stenoses is essential for guiding revascularization and improving outcomes. Although invasive fractional flow reserve (FFR) remains the gold standard for functional lesion assessment, its use is limited by procedural invasiveness, cost, and complexity. CT-derived FFR (FFRct), based on computational fluid dynamics (CFD), was the first major advance in noninvasive physiological assessment, but its adoption has been hindered by intensive off-site computation and dependence on high-quality imaging. This review summarizes the evolution from invasive FFR to AI-driven functional assessment of coronary lesions. We examine the principles and validation of CFD-based FFRct and then focus on the shift toward artificial intelligence, including both machine learning (ML) and deep learning (DL) approaches. These methods range from models using engineered geometric and plaque features trained on large synthetic datasets to end-to-end systems that learn directly from imaging data. We discuss key validation studies evaluating diagnostic accuracy, prognostic value, and clinical utility, with attention to performance in challenging settings such as intermediate stenoses, heavy calcification, and patients with comorbidities. We also highlight major barriers to widespread adoption, including dependence on input data quality, limited explainability, regulatory hurdles, and integration into clinical workflows. Finally, we outline future directions, including AI-enabled virtual PCI planning, multimodal risk stratification, and broader access to functional cardiac assessment. AI has the potential to transform noninvasive coronary imaging by enabling a single CCTA scan to provide rapid, integrated evaluation of anatomy, plaque characteristics, and physiological significance, supporting more personalized care and better clinical outcomes.
Abstract 4003: Path-IO: A deep learning pathomics framework for personalized immunotherapy selection and outcome prediction in metastatic non-small cell lung cancer
Bandyopadhyay, Rukhmini, Hong, Linghzi, Aldea, M, Li, Shenduo , Saad, Maliazurina B., Zhang, Jiexin, Showkatian, Eman , Arrechedera, Claudio A. , Han, Xiaoyu , Kitsel, Yuliya , Ismail, Sherif, Aminu, Muhammad , Zhu, Bo, Wu, Carol C., Carter, B., Chang, Joe Y, Liao, Zhongxing, Ghigna, Maria R., Tran, Hai T., Le, Xiuning, Cascone, Tina , Zhang, Bingnan, Araujo, Haniel A., Altan, Mehmet, Jaffray, David, Gibbons, Don L., Vaporciyan, Ara, Lee, J Jack, Kalhor, Neda , Haymaker, C, Wistuba, Ignacio, Heymach, John V., Lou, Yanyan, Vokes, N. , Soto, Luisa M. Solis, Zhang, Jianjun, Wu, Jia, Aldea, Mihaela , Zullo, Lodovica , Rojas, Frank R. , Saad, Maliazurina B. , Marin, Maricel C., Waqas, Muhammad , Ismail, Sohair , Zhu, Bo , Wu, Carol C. , Liao, Zhongxing , Ghigna, Maria‐Rosa , Soldato, Davide , Tran, Hai T., Le, Xiuning , Zhang, Bingnan , Araújo, Haniel Alves , Altan, Mehmet , Heeke, Simon , Gibbons, Don L , Vaporciyan, Ara A. , Lee, J Jack, Wistuba, Ignacio I. , Heymach, John V. , Soto, Luisa M. Solis , Zhang, Jianjun , Wu, Jia

Mayo Clinic

Cancer Research | May 15, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4003-4003

10.1158/1538-7445.am2026-4003 Get It

Abstract Background: Immune checkpoint inhibitors (ICIs) have improved survival in non-small-cell lung cancer (NSCLC), yet only a subset of patients benefits, and biomarkers like PD-L1 remain limited. Here, we introduce a deep learning-based pathomics framework that utilizes routine H&E-stained slides to predict therapeutic response and survival outcomes in ICI-treated metastatic NSCLC. Methods: The study included 797 ICI-treated NSCLC patients from MD Anderson, with external validation in 280 patients from Mayo Clinic, Gustave Roussy, and the Phase III ICI-naïve LUSC Lung-MAP S1400I trial receiving nivolumab with or without ipilimumab. Path-IO (Pathology-Driven Immunotherapy Optimization) comprised of four major steps: (1) pathologist-verified tissue classifier segmented WSIs into eight compartments—Background, Bronchi, Immune, Lung, Necrosis, Stroma, Tumor, and Vessel—and was validated on TCGA and CPTAC dataset; (2) a survival prediction module generating patient-level risk scores in the MD Anderson cohort and validated across external datasets; (3) integration of Path-IO risk scores with radiomics and clinical features to improve prognostic accuracy; and (4) biological interpretability analyses correlating Path-IO risk immune contexture from multiplex immunofluorescence and transcriptomic signatures from NanoString profiling. Results: Path-IO effectively stratified patients into high and low-risk groups with significant survival differences. In the MD Anderson cohort, it achieved HR = 2.11 (p &lt; 0.001) and HR = 2.51 (p &lt; 0.001) for OS in the discovery and validation sets, and HR = 2.34 (p &lt; 0.001) and HR = 1.87 (p &lt; 0.001) for PFS, respectively. In the multicenter Phase III Lung-MAP S1400I trial, Path-IO achieved HR = 1.78 (p = 0.016) for OS and HR = 2.76 (p = 0.006) for PFS. In external validation, it predicted outcomes in the Gustave Roussy (OS = 1.97, p = 0.003; PFS = 1.51, p = 0.046) and Mayo Clinic (OS = 2.46, p = 0.007; PFS = 2.45, p = 0.027) cohorts. Path-IO outperformed PD-L1 and remained an independent predictor in multivariate analysis (p &lt; 0.001). It enabled data-driven frontline selection between anti-PD-1 monotherapy and chemo-immunotherapy, offering guidance toward more personalized treatment decisions. Integration with radiomics and clinical features further improved predictive accuracy (OS 0.63→0.75; PFS C-index 0.58→0.70), while high Path-IO risk scores correlated with immune-cold phenotypes identified by multiplex immunofluorescence and NanoString transcriptomics. Conclusions: Path-IO demonstrates that deep learning models rooted in histopathologic architecture can generate interpretable and biologically informed survival predictions in NSCLC treated with ICIs. By integrating pathology, radiology, and clinical data, Path-IO provides complementary predictive value beyond established biomarkers such as PD-L1. Citation Format: Rukhmini Bandyopadhyay, Linghzi Hong, Mihaela Aldea, Shenduo Li, Lodovica Zullo, Frank R. Rojas, Maliazurina B. Saad, Maricel C. Marin, Muhammad Waqas, Jiexin Zhang, Eman Showkatian, Claudio A. Arrechedera, Xiaoyu Han, Yuliya Kitsel, Sherif Ismail, Muhammad Aminu, Bo Zhu, Carol C. Wu, Brett W. Carter, Joe Y Chang, Zhongxing Liao, Maria R. Ghigna, Davide Soldato, Hai T. Tran, Xiuning Le, Tina Cascone, Bingnan Zhang, Haniel A. Araujo, Mehmet Altan, Simon Heeke, David Jaffray, Don L. Gibbons, Ara Vaporciyan, J Jack Lee, Neda Kalhor, Cara Haymaker, Ignacio Wistuba, John V. Heymach, Yanyan Lou, Natalie Vokes, Luisa M. Solis Soto, Jianjun Zhang, Jia Wu. Path-IO: A deep learning pathomics framework for personalized immunotherapy selection and outcome prediction in metastatic non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4003.
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy
Investigators, The HCMR, Kolm, Paul, DiMarco, John P., Desai, M Y, Ho, Carolyn Y., Kwong, Raymond Y., Dolman, Sarahfaye , Nickens, Patrice Desvigne, GELLER, NANCY, Kim, Dong-Yun, Schulz-Menger, Jeanette, Friedrich, M G, Maron, Martin S., Appelbaum, Evan, Francis, Gary S., Greenberg, Barry, Jerosch-Herold, Michael, Piechnik, Stefan, Mahmod, Masliza, Jacoby, Daniel L., Baldassare, Lauren A., White, J, Helms, Adam S., Choudhury, Lubna , Michels, Michelle, Salerno, Michael , Heitner, Steven B., Masri, Ahmad, Prasad, Sanjay , Plein, S V E N, Madias, Christopher, Mahrholdt, Heiko , Bucciarelli-Ducci, C, Nightingale, Angus K. , Weinsaft, Jonathan W., McCann, Gerry P., Rossum, Albert van, Germans, Tjeerd , Williamson, Eric E. , Geske, Jeffrey B., Dawson, D, Mongeon, François‐Pierre , Olivotto, Iacopo, Crean, Andrew , Woo, Anna, Owens, Anjali T., Anderson, L , Biagini, Elena, Newby, David E., Andre, Florian, Berry, C, Kim, Bette, Larose, Eric, Abraham, Theodore P., Sherrid, Mark V., Gelfand, Eli V. , Nagueh, Sherif F. , Rimoldi, Ornella, Camici, Paolo, Elstein, Eleanor , Watkins, Hugh, Weintraub, William S., Neubauer, Stefan, Schulz‐Menger, Jeanette , Nightingale, Angus K , Dawson, Dana , Kramer, Christopher M. , Kolm, Paul , Desai, Milind Y. , Ho, Carolyn Y. , Kwong, Raymond Y.K. , Desvigne‐Nickens, Patrice , Kim, Dong-Yun, Friedrich, Matthias G. , Maron, Martin S. , Appelbaum, Evan A., Link, Mark S. , Greenberg, Barry, Jerosch‐Herold, Michael , Piechnik, Stefan Kazimierz , Mahmod, Masliza , Raman, Betty , Jacoby, Daniel Louis , Baldassarre, Lauren A. , White, James A. , Chiribiri, Amedeo , Helms, Adam S. , Michels, Michelle , Bradlow, William M. , Heitner, S B, Masri, Ahmad , Mohiddin, Saidi , Plein, Sven , Madias, Christopher A. , Bucciarelli‐Ducci, Chiara , Weinsaft, Jonathan W. , Kim, Han W. , McCann, Gerry P , Rossum, Albert C. van , Geske, Jeffrey B. , Flett, Andrew S. , Olivotto, Iacopo , Woo, Anna, Owens, Anjali , Sharma, Sanjay , Biagini, Elena , Newby, David E. , André, Florian , Berry, Colin , Larose, Éric , Abraham, Theodore P. , Hays, Allison G , Sherrid, Mark V. , Rimoldi, Ornella , Camici, Paolo G. , Autore, Camillo , Watkins, Hugh , Weintraub, William S. , Neubauer, Stefan

Mayo Clinic

JAMA | May 11, 2026 | Volume: 335 | Issue: 22 | Pages: 1959

10.1001/jama.2026.5633 | PMID 42113540 Get It

Importance Current risk prediction guidelines for hypertrophic cardiomyopathy predict only sudden cardiac death and are imperfect, leading to avoidable deaths and unnecessary implantable cardioverter defibrillators. Objective To combine prospectively collected clinical history, imaging, genetic, and biomarker data to improve risk prediction of adverse events in hypertrophic cardiomyopathy. Design, Setting, and Participants A total of 2750 patients with hypertrophic cardiomyopathy were prospectively enrolled in the registry-based study from 44 sites in North America and Europe with expertise in hypertrophic cardiomyopathy and cardiac magnetic resonance (CMR) imaging. Participants were enrolled from April 1, 2014, to April 7, 2017. Exposures Patients underwent a health history questionnaire, blood sampling for biomarkers and genotyping, and contrast-enhanced CMR. Patients were followed up yearly by telephone and through records review regarding event documentation. Main Outcomes and Measures The predefined composite adjudicated primary end point was time to first event for hypertrophic cardiomyopathy–related deaths; nonfatal sustained ventricular arrhythmias (VAs) requiring cardioversion or defibrillation; and left ventricular (LV) assist device implant or heart transplant. A secondary end point was a composite of sudden cardiac death and nonfatal VA events. The elastic-net method identified the most important predictors. Cox proportional hazards regression assessed associations with time to the first end point. Results Of the 2750 prospectively enrolled patients, 2698 (98%) had analyzable data after 9 were excluded because they had hypertrophic cardiomyopathy phenocopies and 43 withdrew. Of these remaining patients, 1919 (71%) were male, mean age was 50 years (SD, 11 years), and 423 (16%) were from underrepresented racial and minority groups. The mean follow-up was 6.9 years (SD, 2.1 years). The primary event model in 104 patients included LV scar as a percentage of LV mass by late gadolinium enhancement (LGE%; hazard ratio [HR], 1.86; 95% CI, 1.58-2.20; P &amp;lt; .001), LV mass index (HR, 1.09; 95% CI, 1.01-1.17; P = .03), LV end-systolic volume index (HR, 1.28; 95% CI, 1.12-1.46; P &amp;lt; .001 ), all per 10-unit increase, history of heart failure at study entry (HR, 2.89; 95% CI, 1.75-4.77; P &amp;lt; .001), and log N-terminal pro–B-type natriuretic peptide (NT-proBNP; HR, 1.41; 95% CI, 1.17-1.70; P &amp;lt; .001) level per log unit, (C index for all, 0.77). An LGE percentage of the LV mass of 9% or higher substantially increased the primary composite event rate ( P = .001). The secondary sudden cardiac death and VA risk factor model (in 69 patients) included LGE%, LV mass index, LV ejection fraction, and log(NT-proBNP) (C index, 0.76). Conclusions and Relevance These results provide prospective evidence for incorporating cardiac magnetic resonance and NT-proBNP in the evaluation of patients with hypertrophic cardiomyopathy. Trial Registration ClinicalTrials.gov Identifier: NCT01915615
Coronary Microvascular Dysfunction and Lipid Molecules: Pathophysiological Mechanisms, Clinical Assessment, and Therapeutic Implications
Hafez, Abdelrahman , Farina, Juan M. , Awad, Kamal, Pietri, Milagros Pereyra, Scalia, Isabel G. , Sheashaa, Hesham, Abdelfattah, Fatmaelzahraa , Razaghi, Mahshad , Ahmed, Sherif, Ibrahim, Ramzi, Simper, David, Lester, Steven J., Tamarappoo, Balaji, Ayoub, C A, Arsanjani, R A, Arsanjani, Reza , Pereyra, Milagros , Pereyra, Milagros , Sheashaa, Hesham , Abdelfattah, Fatmaelzahraa , Arsanjani, Reza , Farina, Juan M , Scalia, Isabel G , Awad, Kamal , Ahmed, Sherif , Ibrahim, Ramzi

Mayo Clinic

Journal of Personalized Medicine | May 6, 2026 | Volume: 16 | Issue: 5 | Pages: 254

10.3390/jpm16050254 | PMID 42188348 Get It

Coronary microvascular dysfunction (CMD) has emerged as a crucial contributor to cardiovascular morbidity and mortality, particularly in patients with ischemia and non-obstructive coronary arteries (INOCA). The condition arises from a complex interplay of structural and functional abnormalities within the small coronary vessels, driven by underlying molecular mechanisms including endothelial nitric oxide synthase (eNOS) uncoupling, oxidative stress, and chronic inflammation. Lipid metabolism plays a central role in this pathology, especially in the setting of elevated low-density lipoprotein cholesterol (LDL-C). Furthermore, the protective capacity of high-density lipoprotein (HDL) is increasingly understood to depend on its functionality rather than absolute levels, as it can become dysfunctional and pro-inflammatory in pathological states. Emerging evidence has identified lipoprotein(a) [Lp(a)] and triglyceride-rich lipoproteins as significant, independent contributors to microvascular injury. Comprehensive clinical assessment of microvascular dysfunction therefore requires integration of advanced lipid profiling, including apolipoprotein B (ApoB), [Lp(a)], and the triglyceride-glucose (TyG) index with invasive and non-invasive measures of coronary flow reserve to more precisely stratify risk. In this narrative review, we synthesize current observational, mechanistic, and early interventional data linking diverse lipid phenotypes to coronary microvascular dysfunction. We propose a concept of lipid-driven CMD endotypes, such as ApoB-/particle overload, dysfunctional HDL, Lp(a)-mediated risk, and metabolic/TyG-high states, and map these to a practical, mechanism-informed management framework. While intensive LDL-C lowering with high-intensity statins and combination therapy remains guideline-directed care for high-risk patients, evidence for dedicated microvascular benefit from newer lipid and cardiometabolic agents is still largely hypothesis-generating. A personalized approach that aligns lipid phenotyping, CMD endotyping, and existing guideline-based therapies may help refine risk assessment and inform future trials.